Latigo Biotherapeutics (LTGO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LTGO SEC filings page.
This page shows Latigo Biotherapeutics, Inc. (LTGO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings.
Latigo’s balance sheet is liability-heavy, with obligations exceeding assets despite ample current-asset coverage of near-term liabilities.
The combination of$307M in liabilities against$75.5M in assets leaves negative equity, while the 4.0x current ratio indicates that current assets exceed current liabilities; short-term coverage therefore looks different from the company’s overall balance-sheet position.
Liabilities equal
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
We do not publish a peer-relative financial health score for Latigo Biotherapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Latigo Biotherapeutics, Inc.'s EBITDA was -$22.8M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Latigo Biotherapeutics, Inc. reported a net loss of $20.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Latigo Biotherapeutics, Inc. recorded an outflow of $19.6M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Latigo Biotherapeutics, Inc. held $401.2M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Latigo Biotherapeutics, Inc.'s quarterly ROE was -5.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Latigo Biotherapeutics, Inc. invested $17.5M in research and development in Q3 2026. This represents a decrease of 20.8% from the same quarter a year earlier. Against the prior quarter it is down 17.5%.
Latigo Biotherapeutics, Inc. invested $36K in capex in Q3 2026, funding long-term assets and infrastructure. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Not reported for Q3 2026.
LTGO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|
| Total Assets | $408.5M | $64.8M | N/A | $75.5M | N/A | N/A | N/A |
| Current Assets | $406.4M | $59.2M | N/A | $73.8M | N/A | N/A | N/A |
| Cash & Equivalents | $401.2M+283.4% | $55.0M-26.2% | N/A | $69.4M | $104.6M | $74.5M | N/A |
| Short-Term Investments | $0n/m | $0n/m | N/A | $0 | $0 | $0 | N/A |
| Long-Term Investments | $0n/m | $0n/m | N/A | $0 | $0 | $0 | N/A |
| Total Liabilities | $14.5M | $340.8M | N/A | $307.2M | N/A | N/A | N/A |
| Current Liabilities | $14.0M | $51.6M | N/A | $18.4M | N/A | N/A | N/A |
| Non-Current Liabilities | $518K | $289.3M | N/A | $288.7M | N/A | N/A | N/A |
| Total Equity | $394.0Mn/m | -$276.1Mn/m | -$252.6Mn/m | -$231.7M | -$195.8M | -$173.2M | -$149.1M |
| Retained Earnings | -$312.8M | -$291.9M | N/A | -$243.1M | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
LTGO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$231.7M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Latigo Biotherapeutics, Inc. LTGO | FY2025 | N/A | N/A | N/A | $835.4M | — |
| Pharming Group N.V. PHAR | FY2025 | $376.1M | $2.9M | 0.8% | $869.9M | 61/100 |
| MeiraGTx Holdings plc MGTX | FY2025 | $81.4M | -$114.2M | N/A | $864.4M | 64/100 |
| Syndax Pharmaceuticals, Inc. SNDX | FY2025 | $172.4M | -$285.4M | N/A | $858.9M | 61/100 |
| Obsidian Therapeutics, Inc. OBX | FY2025 | $0 | -$100.6M | N/A | $856.5M | — |
| Prime Medicine, Inc. PRME | FY2025 | $4.6M | -$201.1M | N/A | $843.4M | 58/100 |
Where Latigo Biotherapeutics, Inc. Ranks
Frequently Asked Questions
Latigo Biotherapeutics, Inc. (LTGO) had $75.5M in total assets as of fiscal year 2025, including both current and long-term assets.
Latigo Biotherapeutics, Inc. (LTGO) had a current ratio of 4.00 as of fiscal year 2025, which is generally considered healthy.
Latigo Biotherapeutics, Inc. (LTGO) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $835.4M as of Nov 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Latigo Biotherapeutics, Inc. (LTGO) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $835.4M as of Nov 6, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Latigo Biotherapeutics, Inc. (LTGO) has negative shareholder equity of -$231.7M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.